HER2 Positive Breast Carcinoma

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer

Nipple Aspirate Fluid in Detecting Breast Cancer

Validation of TAD in HER-2 with More Than 2 Lymph Nodes

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1